These emerging therapies , Semaglutide , represent a remarkable advancement in treating type 2 diabetes and potentially associated conditions . These drugs are categorized as GLP-1 pathway stimulators, https://roxannufcq469104.yomoblog.com/48725541/tirzepatide-a-comprehensive-examination-into-incretin-agents